Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929.
Karim NA, Miao J, Reckamp KL, Gay CM, Byers LA, Zhao YQ, Redman MW, Carrizosa DR, Wang WL, Petty WJ, Mehta K, Faller BA, Agamah ES, Kasbari SS, Malisetti RK, Kumar A, Schallenkamp J, Alluri KC, Gray JE, Kelly K.
Karim NA, et al. Among authors: wang wl.
J Thorac Oncol. 2024 Nov 4:S1556-0864(24)02431-6. doi: 10.1016/j.jtho.2024.10.021. Online ahead of print.
J Thorac Oncol. 2024.
PMID: 39505259